𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC)

✍ Scribed by Holger Hof; Marc Muenter; Dieter Oetzel; Angelika Hoess; Juergen Debus; Klaus Herfarth

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
347 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

The clinical results after stereotactic single‐dose radiotherapy of nonsmall‐cell lung cancer (NSCLC) stages I and II were evaluated.

METHODS.

Forty‐two patients with biopsy‐proven NSCLC received stereotactic radiotherapy. Patients were treated in a stereotactic body frame and breathing motion was reduced by abdominal compression. The single doses used ranged between 19 and 30 Gy/isocenter.

RESULTS.

After a median follow‐up period of 15 months (range, 1.5–72 months) the actuarial overall survival rates and disease‐free survival rates were 74.5%, 65.4%, 37.4%, and 70.2%, 49.1%, 49.1% at 12, 24, and 36 months after therapy, respectively. The actuarial local tumor control rates were 89.5%, 67.9%, and 67.9% at 12, 24, and 36 months after therapy, respectively. A significant difference (P = .032) in local tumor control was found for patients receiving 26–30 Gy (n = 32) compared with doses of less than 26 Gy (n = 10). The effect of the tumor volume on local tumor control was also evaluated. Although the difference was not statistically significant (P = .078), the subgroup of tumors with a tumor volume of less than 12 cm^3^ (n = 10) experienced no tumor recurrence. Thirteen (31%) patients developed metastases during follow‐up, whereas isolated regional lymph node recurrence was only encountered in 2 patients. No clinically significant treatment‐associated side effects were documented.

CONCLUSIONS.

Stereotactic single‐dose radiotherapy is a safe and effective treatment option for patients with early stage NSCLC not suitable for surgery. Especially for small tumor volumes it seems to be equally effective as hypofractionated radiotherapy, while minimizing the overall treatment time. Cancer 2007. © 2007 American Cancer Society.

📜 SIMILAR VOLUMES

Stage I nonsmall cell lung cancer in pat
Stage I nonsmall cell lung cancer in patients aged ≥75 years : Outcomes after stereotactic radiotherapy
✍ Cornelis J. A. Haasbeek; Frank J. Lagerwaard; Marilisa E. Antonisse; Ben J. Slot 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Background: The number of patients aged > or =75 years who present with a stage i nonsmall cell lung cancer (nsclc) is increasing. elderly patients often have significant comorbidity and may be unfit for surgery. furthermore, surgery in the elderly is associated with increased mortality and morb

Randomized trials of radiotherapy alone
Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis
✍ Jean-Pierre Pignon; Lesley A. Stewart 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 2 views

arino et al.' have performed a meta-analysis using data extracted M from published randomized trials comparing radiotherapy (RT) to RT plus chemotherapy (CT) in Stage IIIA and IIIB unresectable nonsmall cell lung cancer (NSCLC). They identified 14 trials published between 1980 and 1994. The odds rat

Randomized trials of radiotherapy alone
Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis
✍ Pietro Marino; Armando Preatoni; Alessandra Cantoni 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 612 KB

Background. For patients with Stage I11 nonsmall cell lung cancer (NSCLC), radiation is the standard treatment, but survival remains poor. The authors performed a meta-analysis study using clinical trials that evaluated combined radiotherapy plus chemotherapy versus radiotherapy alone in patients wi